These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 27544742)

  • 1. Effect of Optimal Medical Therapy Before Procedures on Outcomes in Coronary Patients Treated With Drug-Eluting Stents.
    Iijima R; Nakamura M; Matsuyama Y; Muramatsu T; Yokoi H; Hara H; Okada H; Ochiai M; Suwa S; Hozawa H; Kawai K; Awata M; Mukawa H; Fujita H; Nanto S;
    Am J Cardiol; 2016 Sep; 118(6):790-796. PubMed ID: 27544742
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Quality of medical management in coronary artery disease.
    Al Shammeri O; Stafford RS; Alzenaidi A; Al-Hutaly B; Abdulmonem A
    Ann Saudi Med; 2014; 34(6):488-93. PubMed ID: 25971821
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Angiography-guided Multivessel Percutaneous Coronary Intervention Versus Ischemia-guided Percutaneous Coronary Intervention Versus Medical Therapy in the Management of Significant Disease in Non-Infarct-related Arteries in ST-Elevation Myocardial Infarction Patients With Multivessel Coronary Disease.
    Perera D; Crake T; Lee V
    Crit Pathw Cardiol; 2018 Jun; 17(2):77-82. PubMed ID: 29768315
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical follow-up 3 years after everolimus- and paclitaxel-eluting stents: a pooled analysis from the SPIRIT II (A Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System in the Treatment of Patients With De Novo Native Coronary Artery Lesions) and SPIRIT III (A Clinical Evaluation of the Investigational Device XIENCE V Everolimus Eluting Coronary Stent System [EECSS] in the Treatment of Subjects With De Novo Native Coronary Artery Lesions) randomized trials.
    Caixeta A; Lansky AJ; Serruys PW; Hermiller JB; Ruygrok P; Onuma Y; Gordon P; Yaqub M; Miquel-Hebert K; Veldhof S; Sood P; Su X; Jonnavithula L; Sudhir K; Stone GW;
    JACC Cardiovasc Interv; 2010 Dec; 3(12):1220-8. PubMed ID: 21232715
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of Optimal Medical Therapy on 10-Year Mortality After Coronary Revascularization.
    Kawashima H; Serruys PW; Ono M; Hara H; O'Leary N; Mack MJ; Holmes DR; Morice MC; Head SJ; Kappetein AP; Thuijs DJFM; Milojevic M; Noack T; Mohr FW; Davierwala PM; Sharif F; McEvoy JW; Onuma Y;
    J Am Coll Cardiol; 2021 Jul; 78(1):27-38. PubMed ID: 34210411
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of diabetes on the benefits from everolimus-eluting stent as compared to first-generation drug-eluting stent in patients with ST elevation myocardial infarction.
    De Luca G; Sauro R; Capasso M; Lanzillo T; Manganelli F; Carbone G; Lanni F; Pagliuca MR; Palmieri V; Serino V; Rosato G; Suryapranata H; Di Lorenzo E
    Diab Vasc Dis Res; 2015 Sep; 12(5):306-14. PubMed ID: 26150193
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evidence-Based Optimal Medical Therapy and Mortality in Patients With Acute Myocardial Infarction After Percutaneous Coronary Intervention.
    Lee K; Han S; Lee M; Kim DW; Kwon J; Park GM; Park MW
    J Am Heart Assoc; 2023 May; 12(10):e024370. PubMed ID: 37158100
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Meta-analysis of everolimus-eluting versus paclitaxel-eluting stents in coronary artery disease: final 3-year results of the SPIRIT clinical trials program (Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients With De Novo Native Coronary Artery Lesions).
    Dangas GD; Serruys PW; Kereiakes DJ; Hermiller J; Rizvi A; Newman W; Sudhir K; Smith RS; Cao S; Theodoropoulos K; Cutlip DE; Lansky AJ; Stone GW
    JACC Cardiovasc Interv; 2013 Sep; 6(9):914-22. PubMed ID: 24050859
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predictors and Outcomes of Routine Versus Optimal Medical Therapy in Stable Coronary Heart Disease.
    Chun S; Qiu F; Austin PC; Ko DT; Mamdani M; Wijeysundera DN; Czarnecki A; Bennell MC; Wijeysundera HC
    Am J Cardiol; 2015 Sep; 116(5):671-7. PubMed ID: 26119653
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Practice patterns and trends in the use of medical therapy in patients undergoing percutaneous coronary intervention in Ontario.
    Garg P; Wijeysundera HC; Yun L; Cantor WJ; Ko DT
    J Am Heart Assoc; 2014 Aug; 3(4):. PubMed ID: 25122664
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Determinants of Insufficient Optimal Medical Therapy after Acute Myocardial Infarction.
    Haraguchi Y; Sakakura K; Yamamoto K; Taniguchi Y; Tsukui T; Seguchi M; Wada H; Momomura SI; Fujita H
    Intern Med; 2020 Jun; 59(12):1489-1495. PubMed ID: 32188806
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Frequency of Stent Thrombosis Risk at 5 Years in Women Versus Men With Zotarolimus-Eluting Compared With Sirolimus-Eluting Stent.
    Ten Haaf M; Appelman Y; Wijns W; Steg G; Mauri L; Rademaker-Havinga T; Wetzels G; Bousquette L; Camenzind E; Boersma E;
    Am J Cardiol; 2016 Oct; 118(8):1178-1186. PubMed ID: 27569387
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Paclitaxel-Eluting versus Everolimus-Eluting Coronary Stents in Diabetes.
    Kaul U; Bangalore S; Seth A; Arambam P; Abhaichand RK; Patel TM; Banker D; Abhyankar A; Mullasari AS; Shah S; Jain R; Kumar PR; Bahuleyan CG;
    N Engl J Med; 2015 Oct; 373(18):1709-19. PubMed ID: 26466202
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Optimal medical therapy improves clinical outcomes in patients undergoing revascularization with percutaneous coronary intervention or coronary artery bypass grafting: insights from the Synergy Between Percutaneous Coronary Intervention with TAXUS and Cardiac Surgery (SYNTAX) trial at the 5-year follow-up.
    Iqbal J; Zhang YJ; Holmes DR; Morice MC; Mack MJ; Kappetein AP; Feldman T; Stahle E; Escaned J; Banning AP; Gunn JP; Colombo A; Steyerberg EW; Mohr FW; Serruys PW
    Circulation; 2015 Apr; 131(14):1269-77. PubMed ID: 25847979
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of Optimal Medical Therapy in the Dual Antiplatelet Therapy Study.
    Resor CD; Nathan A; Kereiakes DJ; Yeh RW; Massaro JM; Cutlip DE; Gabriel Steg P; Hsieh WH; Mauri L;
    Circulation; 2016 Oct; 134(14):989-998. PubMed ID: 27576774
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of an everolimus-eluting stent and a paclitaxel-eluting stent in patients with coronary artery disease: a randomized trial.
    Stone GW; Midei M; Newman W; Sanz M; Hermiller JB; Williams J; Farhat N; Mahaffey KW; Cutlip DE; Fitzgerald PJ; Sood P; Su X; Lansky AJ;
    JAMA; 2008 Apr; 299(16):1903-13. PubMed ID: 18430909
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of everolimus- and paclitaxel-eluting stents in patients with acute and stable coronary syndromes: pooled results from the SPIRIT (A Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System) and COMPARE (A Trial of Everolimus-Eluting Stents and Paclitaxel-Eluting Stents for Coronary Revascularization in Daily Practice) Trials.
    Planer D; Smits PC; Kereiakes DJ; Kedhi E; Fahy M; Xu K; Serruys PW; Stone GW
    JACC Cardiovasc Interv; 2011 Oct; 4(10):1104-15. PubMed ID: 22017936
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Randomized comparison of everolimus-eluting and paclitaxel-eluting stents: two-year clinical follow-up from the Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients with de novo Native Coronary Artery Lesions (SPIRIT) III trial.
    Stone GW; Midei M; Newman W; Sanz M; Hermiller JB; Williams J; Farhat N; Caputo R; Xenopoulos N; Applegate R; Gordon P; White RM; Sudhir K; Cutlip DE; Petersen JL;
    Circulation; 2009 Feb; 119(5):680-6. PubMed ID: 19171853
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of prediabetes and diabetes on 3-year outcome of patients treated with new-generation drug-eluting stents in two large-scale randomized clinical trials.
    Ploumen EH; Pinxterhuis TH; Zocca P; Roguin A; Anthonio RL; Schotborgh CE; Benit E; Aminian A; Danse PW; Doggen CJM; von Birgelen C; Kok MM
    Cardiovasc Diabetol; 2021 Oct; 20(1):217. PubMed ID: 34717627
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Percutaneous coronary intervention vs. optimal medical therapy--the other side of the coin: medication adherence.
    Kocas C; Abaci O; Oktay V; Coskun U; Bostan C; Yildiz A; Arat Ozkan A; Gurmen T; Ersanli M
    J Clin Pharm Ther; 2013 Dec; 38(6):476-9. PubMed ID: 23992279
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.